{"version":"1.0","provider_name":"Fundaci\u00f3 Catalana d&#039;ELA Miquel Valls","provider_url":"https:\/\/fundaciomiquelvalls.org\/es\/","title":"La FDA de EE.UU. aprueba el medicamento Relyvrio para el tratamiento de la ELA","type":"rich","width":600,"height":338,"html":"<blockquote class=\"wp-embedded-content\" data-secret=\"3yc6Vs787Q\"><a href=\"https:\/\/fundaciomiquelvalls.org\/es\/fda-aprueba-medicamento-relyvrio\/\">La FDA de EE.UU. aprueba el medicamento Relyvrio para el tratamiento de la ELA<\/a><\/blockquote><iframe sandbox=\"allow-scripts\" security=\"restricted\" src=\"https:\/\/fundaciomiquelvalls.org\/es\/fda-aprueba-medicamento-relyvrio\/embed\/#?secret=3yc6Vs787Q\" width=\"600\" height=\"338\" title=\"\u00abLa FDA de EE.UU. aprueba el medicamento Relyvrio para el tratamiento de la ELA\u00bb \u2014 Fundaci\u00f3 Catalana d&#039;ELA Miquel Valls\" data-secret=\"3yc6Vs787Q\" frameborder=\"0\" marginwidth=\"0\" marginheight=\"0\" scrolling=\"no\" class=\"wp-embedded-content\"><\/iframe><script>\n\/*! This file is auto-generated *\/\n!function(d,l){\"use strict\";l.querySelector&&d.addEventListener&&\"undefined\"!=typeof URL&&(d.wp=d.wp||{},d.wp.receiveEmbedMessage||(d.wp.receiveEmbedMessage=function(e){var t=e.data;if((t||t.secret||t.message||t.value)&&!\/[^a-zA-Z0-9]\/.test(t.secret)){for(var s,r,n,a=l.querySelectorAll('iframe[data-secret=\"'+t.secret+'\"]'),o=l.querySelectorAll('blockquote[data-secret=\"'+t.secret+'\"]'),c=new RegExp(\"^https?:$\",\"i\"),i=0;i<o.length;i++)o[i].style.display=\"none\";for(i=0;i<a.length;i++)s=a[i],e.source===s.contentWindow&&(s.removeAttribute(\"style\"),\"height\"===t.message?(1e3<(r=parseInt(t.value,10))?r=1e3:~~r<200&&(r=200),s.height=r):\"link\"===t.message&&(r=new URL(s.getAttribute(\"src\")),n=new URL(t.value),c.test(n.protocol))&&n.host===r.host&&l.activeElement===s&&(d.top.location.href=t.value))}},d.addEventListener(\"message\",d.wp.receiveEmbedMessage,!1),l.addEventListener(\"DOMContentLoaded\",function(){for(var e,t,s=l.querySelectorAll(\"iframe.wp-embedded-content\"),r=0;r<s.length;r++)(t=(e=s[r]).getAttribute(\"data-secret\"))||(t=Math.random().toString(36).substring(2,12),e.src+=\"#?secret=\"+t,e.setAttribute(\"data-secret\",t)),e.contentWindow.postMessage({message:\"ready\",secret:t},\"*\")},!1)))}(window,document);\n\/\/# sourceURL=https:\/\/fundaciomiquelvalls.org\/wp-includes\/js\/wp-embed.min.js\n<\/script>\n","thumbnail_url":"https:\/\/fundaciomiquelvalls.org\/wp-content\/uploads\/2022\/10\/ap21113587396498_wide-1ce44202a52d21d0ee24cfd9634baffbabe1c51f-s1400-c100.jpg","thumbnail_width":1400,"thumbnail_height":787,"description":"La compa\u00f1\u00eda AMYLIX PHARMACEUTICALS, INC. anunci\u00f3 el pasado 29 de septiembre la aprobaci\u00f3n del medicamento RELYVRIO para el tratamiento de la ELA, por parte de la Food and Drug Administration (FDA) de los Estados Unidos de Am\u00e9rica."}